Edition:
India

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

30.05USD
8:54pm IST
Change (% chg)

$-0.40 (-1.31%)
Prev Close
$30.45
Open
$30.50
Day's High
$30.55
Day's Low
$29.80
Volume
21,279
Avg. Vol
101,804
52-wk High
$36.35
52-wk Low
$16.30

Latest Key Developments (Source: Significant Developments)

Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Avexis Inc ::REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY.REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS.REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIO'S CONSENT.REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES.  Full Article

Regenxbio Provides Year-End 2017 Corporate Update
Friday, 5 Jan 2018 

Jan 4 (Reuters) - Regenxbio Inc ::REGENXBIO PROVIDES YEAR-END 2017 CORPORATE UPDATE.- ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​.- ‍ANTICIPATE COMPLETING DOSING AND PRESENTING TOPLINE DATA FROM RGX-314 AND RGX-501 TRIALS IN LATE 2018​.- ‍ENDED 2017 WITH GREATER THAN $175 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.SAYS EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION.  Full Article

Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II.REGENXBIO INC - ‍EXPECT TO COMMENCE TRIAL ENROLLMENT IN FIRST HALF OF 2018 FOR RGX-121​.  Full Article

Regenxbio reports third quarter financial results
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Regenxbio Inc :Regenxbio reports third quarter 2017 financial results and recent operational highlights.Q3 loss per share $0.67.Q3 revenue $1.3 million versus $100,000.Q3 revenue view $1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Regenxbio Inc - ‍cash, cash equivalents and marketable securities were $191.1 million as of Sept 30, 2017, compared to $159.0 million as of December 31, 2016​.  Full Article

Regenxbio reports Q2 loss per share $0.55
Tuesday, 9 Aug 2016 

Regenxbio Inc : Q2 loss per share $0.55 . Q2 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S . Regenxbio reports second quarter 2016 financial results and recent operational highlights .Q2 revenue $2.4 million versus I/B/E/S view $2 million.  Full Article

Regenxbio and Biogen enter agreement for development of gene therapy treatments
Monday, 16 May 2016 

Regenxbio Inc : Regenxbio and Biogen enter exclusive license agreement for the development of gene therapy treatments for rare genetic vision disorders . Under terms, Biogen granted worldwide research license to co's NAV AAV8,AAV9 vectors for development of gene therapy product candidates .Co will receive undisclosed upfront payment, ongoing fees, milestone payments and royalties on net sales of products.  Full Article

BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments

* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY